finanzen.net
30.06.2020 23:14

Coronavirus (COVID-19) Update: Daily Roundup

Folgen
Werbung

SILVER SPRING, Md., June 30, 2020 /PRNewswire/ --The U.S. Food and Drug Administration (FDA) today continued to take action in the ongoing response to the COVID-19 pandemic:

  • Today, FDA took action to help facilitate the timely development of safe and effective vaccines to prevent COVID-19 by providing guidance with recommendations related to licensure for those developing COVID-19 vaccines. The guidance, titled "Development and Licensure of Vaccines to Prevent COVID-19," describes the agency's current recommendations regarding the data needed to facilitate the manufacturing, clinical development, and approval of a COVID-19 vaccine. The FDA has the scientific expertise to evaluate any potential COVID-19 vaccine candidate regardless of the technology (e.g., DNA, RNA, protein and viral vector) to produce or administer the vaccine.
    The guidance provides an overview of key considerations to satisfy requirements for chemistry, manufacturing and control, nonclinical and clinical data through development and licensure, and post-licensure safety evaluation. Given the current understanding of SARS-CoV-2 immunology, the goal of development programs at this time should be to support traditional FDA approval by conducting studies to directly evaluate the ability of the vaccine to protect humans from SARS-CoV-2 infection and/or disease. The guidance also notes that, as more is learned about SARS-CoV-2 immunology and vaccine immune responses, consideration may be given to the FDA's Accelerated Approval pathway for vaccine licensure. The guidance also addresses considerations regarding Emergency Use Authorization (EUA) of an investigational vaccine, making clear that an assessment regarding any potential EUA for a COVID-19 vaccine would be made on a case-by-case basis considering the target population, the characteristics of the product, and the totality of the relevant available scientific evidence including preclinical and human clinical study data on the product's safety and effectiveness.
  • FDA issued an Emergency Use Authorization to LifeHope Labs for its molecular-based LifeHope 2019-nCoV Real-Time RT-PCR Diagnostic Panel.
  • In the second FDA Insight podcast, titled "All About COVID-19 Testing," host Dr. Anand Shah, FDA's deputy commissioner for Medical and Scientific Affairs, is joined by Toby Lowe, associate director for FDA's In Vitro Diagnostics Program in the Center for Devices and Radiological Health, discussing "all things" COVID-19 testing.
  • Testing updates:
    • To date, the FDA has authorized 157 tests under EUAs; these include 132 molecular tests, 24 antibody tests, and 1 antigen test.

Additional Resources:

  • FAQs on Testing for SARS-CoV-2
  • Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)
  • Coronavirus Disease 2019 (COVID-19)

Media Contact: Lee.Herring@fda.hhs.gov, 240-402-6386
Consumer Inquiries: 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/coronavirus-covid-19-update-daily-roundup-301086345.html

SOURCE U.S. Food and Drug Administration

Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX tiefer -- Wall Street leichter erwartet -- Deutsche Bank: Positive Trends haben im zweiten Quartal angehalten -- Palantir kündigt IPO an -- Lufthansa, HeidelbergCement, Talanx, Wirecard im Fokus

US-Regierung finanziert Corona-Impfstoffprojekt von Novavax mit 1,6 Milliarden Dollar. Briten wollen in Daimler-Fabrik in Hambach Geländewagen bauen. BaFin prüft möglichen Insiderhandel mit OSRAM-Aktien. DWS erwägt wohl Verkauf von IKS. Aktionäre wollen Abspaltung von Siemens Energy durchwinken. Apple setzt auf Oled-Bildschirme. Weitere positive Reaktion auf Übernahme durch JENOPTIK.

Umfrage

Deutschland debattiert über ein Ende der coronabedingten Maskenpflicht im Handel. Wie ist Ihre Meinung dazu?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
NEL ASAA0B733
TeslaA1CX3T
Ballard Power Inc.A0RENB
Lufthansa AG823212
Deutsche Bank AG514000
BioNTech SE (spons. ADRs)A2PSR2
Daimler AG710000
CommerzbankCBK100
BayerBAY001
Plug Power Inc.A1JA81
Amazon906866
Deutsche Telekom AG555750
BASFBASF11
Infineon AG623100